Obstructive Sleep Apnea (OSA) is no longer viewed merely as a sleep disorder; it is now recognized as a significant contributor to cardiovascular disease (CVD). Research increasingly highlights how OSA exacerbates cardiovascular risk, making early identification and management vital for clinicians seeking to improve patient outcomes.

OSA is characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, leading to intermittent hypoxia and fragmented sleep. These events activate the sympathetic nervous system, elevate blood pressure, and trigger inflammatory pathways, which collectively contribute to hypertension, coronary artery disease, heart failure, and stroke [1,2].

Screening Tools: Identifying OSA in CVD Patients

Several validated tools aid in the early detection of OSA in individuals with cardiovascular conditions:

• STOP-BANG Questionnaire: This simple screening tool evaluates risk factors including     Snoring, Tiredness, Observed apneas, high blood Pressure, Body mass index, Age, Neck circumference, and Gender. It is highly sensitive and useful in cardiovascular settings [3].
• Polysomnography (PSG): Considered the gold standard for OSA diagnosis, PSG provides     comprehensive data on sleep architecture, respiratory events, and oxygen saturation [4]. While effective, its use is often limited to patients with a high pretest probability due to cost and accessibility.
• Peripheral Arterial Tone (PAT): This non-invasive method measures changes in finger arterial tone to detect sleep-disordered breathing events and is a practical alternative in certain clinical contexts [5].

Biomarkers Linking OSA and Cardiovascular Risk

Emerging research identifies several biomarkers that may help clinicians assess the cardiovascular impact of OSA:

• C-Reactive Protein (CRP): Elevated CRP levels indicate systemic inflammation and are associated with increased cardiovascular risk in OSA patients [6].
• Interleukin-6 (IL-6): A pro-inflammatory cytokine often elevated in OSA, contributing to endothelial dysfunction and atherosclerosis [7].
• Adhesion   Molecules (VCAM-1, ICAM-1): Higher levels of these molecules reflect endothelial activation and vascular injury, which are key mechanisms linking OSA to cardiovascular events [8].

Beyond AHI: Phenotyping OSA for Cardiovascular Risk

Traditional reliance on the Apnea-Hypopnea Index (AHI)—the count of breathing interruptions per hour—has limitations in predicting cardiovascular outcomes [9]. Newer metrics such as hypoxic burden (cumulative oxygen desaturation) and traits like loop gain (ventilatory control stability) and arousal thresholds offer a more personalized approach to risk assessment [10].

Clinical Implications and Recommendations

Given the strong association between OSA and cardiovascular disease, clinicians should consider routine OSA screening in patients with resistant hypertension, atrial fibrillation, or unexplained heart failure [11].Early diagnosis and interventions such as continuous positive airway pressure(CPAP) therapy have demonstrated benefits in reducing cardiovascular morbidity and improving quality of life [12].

By integrating validated screening tools, biomarker analysis, and precision phenotyping, healthcare providers can more effectively identify high-risk individuals and tailor management strategies to reduce the substantial burden of OSA-related cardiovascular disease.

References

1. Somers VK et al. Sleep Apnea and Cardiovascular Disease: An American Heart Association Statement. Circulation. 2021.
2. UpToDate. Obstructive Sleep Apnea and Cardiovascular Disease Link.
3. Chung F et al. STOP-BANG Questionnaire: A Practical Approach to Screen for OSA. Chest. 2016.
4. Berry RB et al. The AASM Manual for the Scoring of Sleep and Associated Events. AASM. 2020.
5. Ayas NT et al. Peripheral Arterial Tone Devices in OSA Diagnosis. Chest. 2015.
6. Ryan S et al. CRP as a Marker of Cardiovascular Risk in OSA. Sleep Medicine Reviews. 2018.
7. Nadeem R et al. IL-6 and Cardiovascular Risk in OSA. Journal of Clinical Sleep Medicine. 2017.
8. Kato M et al. Endothelial Dysfunction and Adhesion Molecules in OSA. Circulation. 2013.
9. Malhotra A et al. AHI and Cardiovascular Outcomes: Limitations and Alternatives. Lancet Respir Med. 2019.
10. Eckert DJ et al. Phenotyping OSA: Toward Precision Medicine. Respirology. 2018.
11. Javaheri S et al. Screening for OSA in CVD Clinics. Journal of the American College of Cardiology. 2017.
12. McEvoy RD et al. CPAP and Cardiovascular Prevention in OSA. New England Journal of Medicine. 2016.